Clovis Oncology (CLVS) Tops Q3 EPS by 17c; Raises Rev Outlook
Tweet Send to a Friend
Clovis Oncology (NASDAQ: CLVS) reported Q3 EPS of ($1.72), $0.17 better than the analyst estimate of ($1.89). Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE